These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 36830750)

  • 1. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
    Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
    Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
    Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early versus standard management of chimeric antigen receptor therapy toxicities and management's impact on safety and efficacy.
    Gaffney KJ; Davis JA; McGann M; Edwards K; Ahmed Z; Butcher C; Greenwell B; Hess BT; Hashmi H
    J Oncol Pharm Pract; 2024 Jan; 30(1):151-158. PubMed ID: 37097891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of long-term corticosteroids in patients treated with CAR T-cell therapy.
    Hashmi H; McGann M; Greenwell BI
    J Oncol Pharm Pract; 2023 Mar; 29(2):473-476. PubMed ID: 35635259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
    Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
    Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy.
    Pu Y; Zhao Y; Qi Y; Liu Y; Zhang M; Xiao X; Lyu H; Meng J; Zhu H; Xu K; Han W; Zhao M
    Int Immunopharmacol; 2024 Mar; 130():111761. PubMed ID: 38422769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma.
    De Philippis C; Mannina D; Giordano L; Costantini E; Marcheselli S; Mariotti J; Sarina B; Taurino D; Santoro A; Bramanti S
    Transplant Cell Ther; 2023 Jul; 29(7):429.e1-429.e6. PubMed ID: 36966874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma.
    Costa BA; Flynn J; Nishimura N; Devlin SM; Farzana T; Rajeeve S; Chung DJ; Landau HJ; Lahoud OB; Scordo M; Shah GL; Hassoun H; Maclachlan K; Hultcrantz M; Korde N; Lesokhin AM; Shah UA; Tan CR; Giralt SA; Usmani SZ; Nath K; Mailankody S
    Blood Cancer J; 2024 May; 14(1):84. PubMed ID: 38802346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How I treat refractory CRS and ICANS after CAR T-cell therapy.
    Jain MD; Smith M; Shah NN
    Blood; 2023 May; 141(20):2430-2442. PubMed ID: 36989488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
    Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
    Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
    Kotch C; Barrett D; Teachey DT
    Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
    [No Abstract]   [Full Text] [Related]  

  • 14. Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy.
    Davis JA; Gaffney KJ; McGann M; Smith D; Edwards K; Baldino E; Bakos K; Butcher C; Greenwell B; Hess BT; Hashmi H
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e14-e18. PubMed ID: 36319568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of early tocilizumab intervention on patients with cytokine release syndrome following chimeric antigen receptor T cell therapy].
    Zhou LL; Ye SG; Li P; Tang XC; Liang AB
    Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1022-1026. PubMed ID: 38503526
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.
    Wang X; Zhang B; Zhang Q; Zhou H; Sun Q; Zhou Y; Li T; Zhou D; Shen Z; Zhang J; Li P; Liang A; Zhou K; Han L; Hu Y; Yang Y; Cao J; Li Z; Xu K; Sang W
    Cancer; 2024 Apr; ():. PubMed ID: 38578977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
    Gardner RA; Ceppi F; Rivers J; Annesley C; Summers C; Taraseviciute A; Gust J; Leger KJ; Tarlock K; Cooper TM; Finney OC; Brakke H; Li DH; Park JR; Jensen MC
    Blood; 2019 Dec; 134(24):2149-2158. PubMed ID: 31697826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
    Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
    Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
    Le RQ; Li L; Yuan W; Shord SS; Nie L; Habtemariam BA; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Aug; 23(8):943-947. PubMed ID: 29622697
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.